4 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
| Phase 1 | 1 | Unknown 1 |
Follow CCT239065: new trials by email Literature Review of CCT239065 trials Research Report on CCT239065
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation HLX208 - Metastatic Colorectal Cancer, mCRC | Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2022-03-23 | 2023-08-08 |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation HLX208 - Anaplastic Thyroid Cancer, ATC | Phase 1 / Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-10 | 2023-08-21 |
| The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation HLX208 - Langerhans Cell Histiocytosis, Erdheim-Chester Disease | Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-06 | 2023-08-08 |
| The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment HLX208, Cetuximab Injection [Erbitux] - CRC | Phase 2 | Unknown | Shanghai Henlius Biotech | 50 | 2021-08-11 | 2023-08-21 |
Colorectal Neoplasms (1) · Erdheim-Chester Disease (1) · Histiocytosis, Langerhans-Cell (1) · Thyroid Carcinoma, Anaplastic (1)
China (4)